BioMark Diagnostics, Inc.

Recent News

  • BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

    Vancouver, British Columbia--(Newsfile Corp. - November 25, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, today reports its operational update for the second quarter ended September 30, 2021. The Company also announces it intends to extend the warrant exercise term on a continuing effort to improve corporate value for its shareholders. Highlights of the Second QuarterIn...

    2021-11-25 8:30 AM EST
  • BioMark obtiens un financement pour accélérer le développement de sa technologie de biopsie liquide au Québec

    Vancouver, British Columbia--(Newsfile Corp. - 16 novembre 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) («BioMark»), une société de biotechnologie qui se consacre au développement de tests diagnostiques pour les cancers difficiles à détecter et à traiter, est heureuse d'annoncer que sa filiale québécoise en propriété exclusive BioMark Diagnostic Solutions Inc. («BDS») recevra des services-conseils ainsi qu'un financement pouvant atteindre 169 550 $ CAD dans le cadre du Programme d'aide à la recherche industrielle du Conseil...

    2021-11-16 8:30 AM EST
  • BioMark Secures Funding to Accelerate Development of Its Liquid Biopsy Assay in Quebec

    Vancouver, British Columbia--(Newsfile Corp. - November 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc ("BDS")., is receiving advisory services and funding of up to CAD $169,550 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of...

    2021-11-16 8:30 AM EST
  • BioMark Recognizes and Supports the Lung Cancer Awareness Month

    Vancouver, British Columbia--(Newsfile Corp. - November 10, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it recognizes and wanted to raise awareness of the challenges that come from a diagnosis of lung cancer. There are fundamental strides being made in both the early diagnosis and more effective therapeutic intervention that will better smooth...

    2021-11-10 8:30 AM EST
  • Diagnostic and Therapeutic Benefits of BioMark's Cancer Marker Featured in Two Poster Presentations at the Canadian Cancer Research Conference

    Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the diagnostic and therapeutic capabilities of its SSAT cancer marker will be featured in virtual posted presentation at the sixth biennial Canadian Cancer Research Conference to be held virtually from Nov 8-11, 2021.Investigators, led by CancerCare Manitoba researchers and...

    2021-11-08 8:30 AM EST
  • Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021

    Vancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that it will hold a virtual stand at the III annual Congress of the International Society of Liquid Biopsy to showcase its innovative technology to a key audience with compelling data from previous studies that demonstrates the ability of its assays...

    2021-10-18 8:30 AM EDT
  • Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy

    Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen With or Without Immunotherapy. Since immunotherapy is now standard of care for lung cancer, BioMark amended the protocol to include study...

    2021-06-29 8:30 AM EDT
  • BioMark reçoit une subvention de 825 000 $ pour développer son test de biopsie liquide pour le dépistage du cancer du poumon

    Vancouver, British Columbia--(Newsfile Corp. - 1 juin 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) («BioMark») est heureuse d'annoncer aujourd'hui que sa filiale en propriété exclusive BioMark Diagnostic Solutions Inc. ("BDS") a reçu un financement pour le développement d'un test de dépistage du cancer du poumon à un stade précoce en utilisant la technologie de biopsie liquide exclusive de BioMark. Le montant global de la subvention s'élève à environ 825 000$ et la majorité du financement...

    2021-06-01 8:30 AM EDT